Product Description
Mechanisms of Action: Gram+ Bacteria Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Vaginal
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Austria | Bangladesh | Belgium | Brazil | Bulgaria | Chile | Colombia | Dominican Republic | Egypt | France | Germany | Hong Kong | Hungary | Indonesia | Ireland | Italy | Lebanon | Malaysia | Mexico | New Zealand | Pakistan | Philippines | Portugal | Russia | South Africa | Spain | Sri Lanka | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Medinova AG
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Vaginosis, Bacterial|Vaginal Diseases|Candidiasis, Vulvovaginal
Phase 3: Vaginal Diseases|Vaginosis, Bacterial|Gram-Positive Bacterial Infections|Pseudomonas Infections|Gram-Negative Bacterial Infections
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2500098319 |
ChiCTR2500098319 | N/A |
Recruiting |
Respiratory Tract Infections|Pharyngitis|Tonsillitis |
2026-02-28 |
|||
CTR20240880 |
CTR20240880 | N/A |
Completed |
Gingivitis|Pharyngitis|Oral Ulcer |
2024-04-08 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT04057482 |
NCT04057482 | N/A |
Completed |
Vaginal Diseases|Vaginosis, Bacterial |
2017-12-01 |
2019-08-21 |
Primary Endpoints|Treatments |
|
2006-004399-11 |
2006-004399-11 | P3 |
Completed |
Gram-Negative Bacterial Infections|Gram-Positive Bacterial Infections|Pseudomonas Infections |
2009-05-13 |
2022-03-12 |
Treatments |
|
2006-004398-89 |
2006-004398-89 | P3 |
Completed |
Vaginosis, Bacterial |
2008-08-28 |
2025-07-09 |
||
NCT01125410 |
Med380104 | P3 |
Completed |
Vaginal Diseases|Vaginosis, Bacterial |
2008-07-01 |
2019-03-19 |
Treatments |
|
NCT05788991 |
MNFM380119 | P4 |
Terminated |
Vaginal Diseases|Vaginosis, Bacterial |
2022-08-25 |
2023-03-30 |
Primary Endpoints|Treatments |
|
2020-002489-15 |
2020-002489-15 | P4 |
Terminated |
Vaginosis, Bacterial |
2022-08-15 |
2022-03-13 |
Treatments |
|
2019-002819-25 |
DEVA | P4 |
Unknown status |
Vaginosis, Bacterial |
2022-03-22 |
2022-03-13 |
Treatments |
|
NCT02242695 |
Flu-380112 | P4 |
Completed |
Candidiasis, Vulvovaginal |
2015-12-01 |
2019-03-20 |
Treatments |